Document Detail


Dexrazoxane as a cardioprotectant in children receiving anthracyclines.
MedLine Citation:
PMID:  21051660     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Anthracyclines play a critical role in the treatment of a variety of childhood cancers. However, the cumulative cardiotoxic effects of anthracyclines limit the use of these agents in many treatment regimens. Dexrazoxane is a cardioprotectant that significantly reduces the incidence of adverse cardiac events in women with advanced breast cancer treated with doxorubicin-containing regimens. Clinical evidence for the efficacy of dexrazoxane as a cardioprotectant in children, especially from randomized clinical trials, is limited, but the available data support a short-term cardioprotective effect. Long-term follow-up in children treated with dexrazoxane has not been reported. Dexrazoxane's impact on the antitumor effect and toxicity profile of the anthracyclines and the role of dexrazoxane in the development of secondary malignant neoplasms in patients who received dexrazoxane are reviewed. Based on the available data, dexrazoxane appears to be a safe and effective cardioprotectant in children, and it does not appear to alter overall survival times in children with cancer. Continued follow-up from previous trials is needed to determine the long-term effect of dexrazoxane on cardiac outcomes and quality of life.
Authors:
Dana M Sepe; Jill P Ginsberg; Frank M Balis
Publication Detail:
Type:  Journal Article     Date:  2010-11-04
Journal Detail:
Title:  The oncologist     Volume:  15     ISSN:  1549-490X     ISO Abbreviation:  Oncologist     Publication Date:  2010  
Date Detail:
Created Date:  2010-12-01     Completed Date:  2011-06-07     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1220-6     Citation Subset:  IM    
Affiliation:
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. sepe@email.chop.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anthracyclines / administration & dosage,  adverse effects*,  therapeutic use
Antineoplastic Agents / adverse effects*
Arrhythmias, Cardiac / chemically induced*,  prevention & control
Cardiomyopathies / chemically induced*,  prevention & control
Cardiotonic Agents / administration & dosage,  adverse effects,  therapeutic use*
Child
Child, Preschool
Heart Failure / chemically induced*,  prevention & control
Humans
Razoxane / administration & dosage,  adverse effects,  therapeutic use*
Risk Factors
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Anthracyclines; 0/Antineoplastic Agents; 0/Cardiotonic Agents; 21416-87-5/Razoxane
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.
Next Document:  Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome ...